JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.85B |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$1.5B |
| 3 |
JPMorgan BetaBuilders Canada ETF
BBCA
|
+$1.21B |
| 4 |
Chevron
CVX
|
+$1.08B |
| 5 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$986M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.61B |
| 2 |
Occidental Petroleum
OXY
|
+$1.36B |
| 3 |
Merck
MRK
|
+$913M |
| 4 |
Visa
V
|
+$801M |
| 5 |
AT&T
T
|
+$771M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.95% |
| 2 | Technology | 12.9% |
| 3 | Financials | 12.36% |
| 4 | Healthcare | 9.31% |
| 5 | Consumer Discretionary | 8.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5026
Donegal Group Class A
DGICA
$679M
| $43K | ﹤0.01% |
2,836
-10,661
| -79% | -$150K |
2017 Q4
6 quarters
|
|
5027
Franklin Financial Services
FRAF
$284M
| $43K | ﹤0.01% |
+1,151
| New | +$44.2K |
2019 Q2
0 quarters
|
|
5028
Marchex
MCHX
$61.6M
| $43K | ﹤0.01% |
9,524
-40,523
| -81% | -$194K |
2018 Q4
2 quarters
|
|
5029
MainStreet Bancshares
MNSB
$179M
| $43K | ﹤0.01% |
+1,950
| New | +$46.1K |
2019 Q2
0 quarters
|
|
5030
MVB Financial
MVBF
$392M
| $43K | ﹤0.01% |
2,592
+503
| +24% | +$8.21K |
2018 Q2
4 quarters
|
|
5031
Ohio Valley Banc Corp
OVBC
$210M
| $43K | ﹤0.01% |
1,137
-1,370
| -55% | -$51.4K |
2017 Q4
6 quarters
|
|
5032
Schwab US Broad Market ETF
SCHB
$45.1B
| $43K | ﹤0.01% |
3,666
-3,168
| -46% | -$36.6K |
2017 Q1
9 quarters
|
|
5033
Sportsman's Warehouse
SPWH
$44.6M
| $43K | ﹤0.01% |
11,656
-171,347
| -94% | -$729K |
2017 Q3
7 quarters
|
|
5034
Tiptree Inc
TIPT
$650M
| $43K | ﹤0.01% |
6,831
+356
| +5% | +$2.19K |
2017 Q4
6 quarters
|
|
|
TBCH
5035
Turtle Beach Corp
TBCH
$249M
| $43K | ﹤0.01% |
3,700
-85,187
| -96% | -$902K |
2018 Q2
4 quarters
|
|
|
ENZ
5036
DELISTED
Enzo Biochem, Inc.
ENZ
| $43K | ﹤0.01% |
12,121
+1,377
| +13% | +$4.85K |
2017 Q3
7 quarters
|
|
|
PBIP
5037
DELISTED
Prudential Bancorp, Inc.
PBIP
| $43K | ﹤0.01% |
2,403
+237
| +11% | +$4.13K |
2017 Q4
6 quarters
|
|
|
CNST
5038
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $43K | ﹤0.01% |
4,246
+398
| +10% | +$4.43K |
2018 Q3
3 quarters
|
|
5039
Abeona Therapeutics
ABEO
$292M
| $42K | ﹤0.01% |
354
+49
| +16% | +$8.21K |
2017 Q4
6 quarters
|
|
|
ALLK
5040
CALL
DELISTED
Allakos
ALLK
| $42K | ﹤0.01% |
+1,000
| New | +$41K |
2019 Q2
0 quarters
|
|
|
CLPR
5041
Clipper Realty
CLPR
$51.2M
| $42K | ﹤0.01% |
3,958
-33,082
| -89% | -$426K |
2017 Q4
6 quarters
|
|
5042
FTAI Aviation
FTAI
$17B
| $42K | ﹤0.01% |
+3,261
| New | +$44.5K |
2019 Q2
0 quarters
|
|
5043
Great Elm Capital Corp
GECC
$68.9M
| $42K | ﹤0.01% |
800
-500
| -38% | -$25.8K |
2019 Q1
1 quarter
|
|
5044
Medallion Financial
MFIN
$274M
| $42K | ﹤0.01% |
6,614
+4,414
| +201% | +$30.3K |
2019 Q1
1 quarter
|
|
5045
Novavax
NVAX
$1.83B
| $42K | ﹤0.01% |
6,833
-62,195
| -90% | -$489K |
2014 Q3
19 quarters
|
|
5046
Invesco S&P SmallCap 600 Revenue ETF
RWJ
$1.98B
| $42K | ﹤0.01% |
2,049
-21,468
| -91% | -$460K |
2015 Q2
16 quarters
|
|
|
SBBP
5047
DELISTED
Strongbridge Biopharma plc.
SBBP
| $42K | ﹤0.01% |
+12,941
| New | +$47.5K |
2019 Q2
0 quarters
|
|
|
DNBF
5048
DELISTED
DNB Financial Corp
DNBF
| $42K | ﹤0.01% |
954
-345
| -27% | -$14.2K |
2017 Q4
6 quarters
|
|
|
STEX
5049
Streamex Corp
STEX
$69.9M
| $41K | ﹤0.01% |
430
+380
| +760% | +$27.6K |
2019 Q1
1 quarter
|
|
5050
Galectin Therapeutics
GALT
$374M
| $41K | ﹤0.01% |
10,136
-178,555
| -95% | -$773K |
2019 Q1
1 quarter
|
|
Similar funds
JP Morgan Chase's Q2 2019 Portfolio in Review
As of Q2 2019, JP Morgan Chase held 6,226 positions worth $511B, up 4.5% from $490B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
JP Morgan Chase's Q2 2019 filing shows 458 new, 2,668 increased, 2,116 reduced and 420 closed positions. Its largest new stake was Corteva: 13,119,143 shares worth $388M. The largest sale was iShares 1-3 Year Treasury Bond ETF, an estimated $3.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, up from 27% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q2 2019 buy was Corteva: 13,119,143 shares worth $388M.
- JP Morgan Chase added most to iShares 0-1 Year Treasury Bond ETF in Q2 2019, an estimated $3.85B increase.
- JP Morgan Chase's biggest Q2 2019 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.61B.
- JP Morgan Chase fully exited Goldcorp Inc in Q2 2019, selling an estimated $131M.
- JP Morgan Chase's ten largest holdings make up 16% of its $511B portfolio in Q2 2019.
- JP Morgan Chase opened 458 new positions and closed 420 in Q2 2019.
- JP Morgan Chase's portfolio value rose 4.5% quarter-over-quarter to $511B.
Based on JP Morgan Chase's 13F filing for Q2 2019, filed 7 Aug 2019.